Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This content is for healthcare professionals only.

Please confirm you are a healthcare professional.

Yes
No
Session III: CAR-T in CLL

Presentations
Update CLL CAR-T trial landscape/JCAR
Tanya Siddiqi
29 October, 2020
The role of CLL tumor cells in resistance to anti-CAR-T cell therapy
Joseph Melenhorst
29 October, 2020
Long-term outcomes of anti-CD19 CAR-T in R/R CLL
David Porter
29 October, 2020
Previous session View all sessions Next session

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals